Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, 610 Walnut St, Madison, WI 53726, USA.
Radiology. 2011 Nov;261(2):487-98. doi: 10.1148/radiol.11102411. Epub 2011 Aug 3.
To estimate the cost-effectiveness of computed tomographic (CT) colonography for colorectal cancer (CRC) screening in average-risk asymptomatic subjects in the United States aged 50 years.
Enrollees in the American College of Radiology Imaging Network National CT Colonography Trial provided informed consent, and approval was obtained from the institutional review board at each site. CT colonography performance estimates from the trial were incorporated into three Cancer Intervention and Surveillance Modeling Network CRC microsimulations. Simulated survival and lifetime costs for screening 50-year-old subjects in the United States with CT colonography every 5 or 10 years were compared with those for guideline-concordant screening with colonoscopy, flexible sigmoidoscopy plus either sensitive unrehydrated fecal occult blood testing (FOBT) or fecal immunochemical testing (FIT), and no screening. Perfect and reduced screening adherence scenarios were considered. Incremental cost-effectiveness and net health benefits were estimated from the U.S. health care sector perspective, assuming a 3% discount rate.
CT colonography at 5- and 10-year screening intervals was more costly and less effective than FOBT plus flexible sigmoidoscopy in all three models in both 100% and 50% adherence scenarios. Colonoscopy also was more costly and less effective than FOBT plus flexible sigmoidoscopy, except in the CRC-SPIN model assuming 100% adherence (incremental cost-effectiveness ratio: $26,300 per life-year gained). CT colonography at 5- and 10-year screening intervals and colonoscopy were net beneficial compared with no screening in all model scenarios. The 5-year screening interval was net beneficial over the 10-year interval except in the MISCAN model when assuming 100% adherence and willingness to pay $50,000 per life-year gained.
All three models predict CT colonography to be more costly and less effective than non-CT colonographic screening but net beneficial compared with no screening given model assumptions.
评估在 50 岁美国一般风险无症状人群中进行 CT 结肠成像(CTC)筛查结直肠癌(CRC)的成本效益。
美国放射学院成像网络国家 CTC 结肠成像试验的参与者提供了知情同意书,并获得了每个站点机构审查委员会的批准。试验中的 CTC 结肠成像性能估算值被纳入三个癌症干预和监测建模网络 CRC 微观模拟中。模拟了对美国 50 岁人群进行每 5 年或 10 年一次的 CTC 筛查的生存和终生成本,与结肠镜检查、软性乙状结肠镜检查联合使用敏感非脱水粪便潜血试验(FOBT)或粪便免疫化学试验(FIT)以及无筛查的情况进行了比较。考虑了完美和降低的筛查依从性情况。从美国医疗保健部门的角度出发,估计了增量成本效益和净健康收益,假设贴现率为 3%。
在所有三种模型中,在 100%和 50%的依从性情况下,5 年和 10 年的 CTC 筛查间隔比 FOBT 联合软性乙状结肠镜检查更昂贵,效果更差。结肠镜检查也比 FOBT 联合软性乙状结肠镜检查更昂贵,效果更差,除非在 CRC-SPIN 模型中假设 100%的依从性(增量成本效益比:每获得一个生命年增加 26300 美元)。在所有模型情景中,与不筛查相比,5 年和 10 年的 CTC 筛查间隔以及结肠镜检查都是有益的。除了在 MISCAN 模型中假设 100%的依从性和愿意为每获得一个生命年支付 50000 美元的情况下,5 年的筛查间隔比 10 年的筛查间隔更有益。
所有三种模型都预测 CTC 比非 CTC 筛查更昂贵,效果更差,但在模型假设的情况下,与不筛查相比,都是有益的。